News
Zacks.com on MSN2h
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis StudyNektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.
A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...
NKTR shares climb to $9.54 amid investor optimism and Phase IIb REZOLVE-AD results; EPS forecasts up 10.5% in 30 days.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback